In addition, PPAR agonists, such as bezafibrate and elafibranor, downregulate the expression of bile acid synthase CYP7A1, which is the key regulator of bile acid synthesis, thereby having beneficial effects on PBC in (pre)clinical trials [36,56,66]. Here, PPARA is linked to primary biliary cholangitis.